New therapeutic developments for mastocytosis;Neues zur therapie der mastozytose

Aktuelle Dermatologie

Volumn 35, Issue 12, 2009, Pages 491-495

  Brockow, K ^a   Grosber, M ^a   Holzle K ^a   Behrendt, H ^a   Ring, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLADRIBINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOSTATIC AGENT; DASATINIB; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; INSECT VENOM; LENALIDOMIDE; OMALIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; PSORALEN; THALIDOMIDE; VITAMIN D;

ANAPHYLAXIS; CLINICAL FEATURE; DRUG TOLERABILITY; EMERGENCY CARE; GENERAL ANESTHESIA; HUMAN; IMMUNOTHERAPY; MASTOCYTOSIS; PATHOGENESIS; PUVA; RECURRENT DISEASE; REVIEW; SELF MEDICATION; TOPICAL TREATMENT; TREATMENT INDICATION; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION;

EID: 71849092834     PISSN: 03402541     EISSN: 1438938X     Source Type: Journal    
DOI: 10.1055/s-0029-1214736     Document Type: Review

References (34)

1. Brockow K. Urticaria pigmentosa. Immunol Allergy Clin North Am 2004 24 287-316
2. Brockow K, Metcalfe D D. Mastocytosis. Curr Opin Allergy Clin Immunol 2001 1 449-454
3. Hartmann K, Brockow K, Grabbe J, et al. Mastozytose. Allergo Journal 2009 18 196-207
4. Brockow K, Ring J. Mastozytose Ursache anaphylaktoider Reaktionen. Allergo-Journal 2006 15 143-152
5. Brockow K. Schweregradmarker der systemischen Mastozytose. Allergo-Journal 2006 15 273-279
6. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008 63 226-232
7. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007 37 1547-1555
8. Ring J, Brockow K, Duda D, et al. Akuttherapie anaphylaktischer Reaktionen. Allergo Journal 2007 16 420-434
9. Brockow K, Ring J, Przybilla B, Ruëff F. Klinik und Therapie der Anaphylaxie bei Mastozytose. Allergo Journal 2008 17 556-562
10. Carter M C., Uzzaman A, Scott L M., Metcalfe D D., Quezado Z. Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg 2008 107 422-427
11. Rueff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006 6 284-288
12. Przybilla B, Müller U, Jarisch R, Ruëff F. Erhöhte basale Serumtryptasekonzentration oder Mastozytose als Risikofaktor der Hymenopterengiftallergie. Allergo-Journal 2004 13 440-442 (Pubitemid 39481609)
13. Bonadonna P, Zanotti R, Caruso B, et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 2008 121 256-257
14. Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez M I., et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008 121 519-526
15. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008 63 376-378
16. Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol 2008 18 225-226
17. Carter M C., Robyn J A., Bressler P B., et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007 119 1550-1551
18. Siebenhaar F, Kuhn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 2007 120 213-215
19. Gobello T, Mazzanti C, Sordi D, et al. Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J Am Acad Dermatol 2003 49 679-684
20. Heide R, de Waard-van der Spek F B., den Hollander J C., et al. Efficacy of 25% diluted fluticasone propionate 0.05% cream as wet-wrap treatment in cutaneous mastocytosis. Dermatology 2007 214 333-335
21. Hartmann K, Siebenhaar F, Belloni B, et al. Topical treatment with the raft modulator miltefosine a novel therapeutic option for mastocytosis? British Journal of Dermatology, submitted 2008
22. Akin C, Brockow K, DAmbrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003 31 686-692
23. Akin C, Fumo G, Yavuz A S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004 103 3222-3225
24. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007 37 435-453
25. Quintas-Cardama A, Kantarjian H, Verstovsek S. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol 2007 82 1124
26. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008 14 3906-3915
27. Damaj G, Bernit E, Ghez D, et al. Thalidomide in advanced mastocytosis. Br J Haematol 2008 141 249-253
28. Kluin-Nelemans H C., Ferenc V, van Doormaal J J., et al. Lenalidomide therapy in systemic mastocytosis. Leuk Res 2009 33 e19-22
29. Verstovsek S, Akin C, Manshouri T, et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006 30 1365-1370
30. Tanaka A, Konno M, Muto S, et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005 105 2324-2331
31. Gotlib J, Berube C, Growney J D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005 106 2865-2870
32. Schatz M, Verhoef G, Gattermann N, et al. A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM). Journal of Clinical Oncology 2006 24 6588 (Abstr.)
33. Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006 37 353-358
34. Gleixner K V., Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007 92 1451-1459